camptothecin/podophyllotoxin (NEV-801) / Neovia Oncology - LARVOL DELTA

Creatv Bio…and Neovia Oncology…announced the signing of a strategic partnership agreement to collaborate on Neovia's upcoming studies treating patients with advanced multiple drug resistant solid tumors who are entering late lines of therapy (PRNewswire) - "The collaboration is expected to generate translational and biomarker data designed to improve patient stratification and deepen understanding of treatment response dynamics in advanced cancers. In addition to its development as a systemic therapy, Neovia is also evaluating the broader platform potential of NEV-801 in next-generation oncology applications, including antibody-drug conjugate (ADC) strategies."

Licensing / partnership • Oncology

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=78 | Completed | Sponsor: Neovia Oncology Ltd. | Recruiting ➔ Completed

First-in-human • Trial completion • Oncology • Solid Tumor

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2016 ➔ Dec 2016

Enrollment open • Trial initiation date • Biosimilar • Oncology

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Jul 2018 ➔ Dec 2019; Trial primary completion date: Jul 2018 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date